CN1552715A - Preparation of dehydrate catharahhine from intermediate of vinorelbine synthesis - Google Patents
Preparation of dehydrate catharahhine from intermediate of vinorelbine synthesis Download PDFInfo
- Publication number
- CN1552715A CN1552715A CNA03136439XA CN03136439A CN1552715A CN 1552715 A CN1552715 A CN 1552715A CN A03136439X A CNA03136439X A CN A03136439XA CN 03136439 A CN03136439 A CN 03136439A CN 1552715 A CN1552715 A CN 1552715A
- Authority
- CN
- China
- Prior art keywords
- vinorelbine
- reagent
- reaction
- david smail
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A process for preparing the dewatered velban as the intermediate of vinorelbine and its medicinal salt features that its dewatering agent is the ammonium chloromethylene dimethyl chloride prepared from DMF and SOCl2 or oxalyl chloride. Its advantages are high purity and output rate, and high output rate of vinorelbine.
Description
The present invention relates to chemical pharmacy field, particularly, the present invention relates to a kind of synthetic method of synthetic intermediate vinealeucoblastine(VLB) of new anticarcinogen vinorelbine.
Vinorelbine (trade(brand)name: nvelbine (Navelbing)) be a kind of novel semi-synthetic vinca anticarcinogen.Because its particular structure changes, make it littler and stronger anti-tumor activity arranged than other vinca alkaloids neurotoxicities such as vincaleucoblastine, vincristine(VCR), vindesines.Bibliographical informations such as US4307100A the synthetic method of multiple vinorelbine, still, because the complex structure of vinorelbine, the productive rate of these synthetic methods is all lower, the synthesis yield of intermediate F 81097 especially wherein is low.The inventor finds through long term studies, by using new technical schemes such as dewatering agent, can improve the productive rate of synthetic F 81097 significantly, finishes the present invention thus.
The novel method that the purpose of this invention is to provide a kind of synthetic F 81097;
Another object of the present invention has provided the purposes of Weir David Smail reagent in the synthetic F 81097 by vinealeucoblastine(VLB).
The synthetic of vinorelbine and pharmacologically acceptable salt thereof generally is to be raw material with the Vinblastine sulphate, prepares vinorelbine and pharmacologically acceptable salt thereof through steps such as dehydration, bromination, the ring salifies that contracts.In the prior art, the first step dehydration reaction adopts POCl usually
3Or SOCl
2The dehydration of/DMF reagent.But it is many to be to use these reagent to exist side reaction, the component complexity, and many shortcomings such as easy emulsification during extraction make that dehydration reaction and total synthetic yield are on the low side.The inventor is by changing yield and the quality that dewatering agent improves the first step dehydration reaction.The reagent that the present invention uses is Weir David Smail reagent (Vilsmeier Reagent[ClCH=N (CH
3)
2Cl], promptly chloromethane is pitched alkyl dimethyl ammonium chloride), this reagent can be by DMF and SOCl
2Or oxalyl chloride makes.By method of the present invention and method of the prior art are compared, as can be seen, use Vilsmeier Reagent[ClCH=N (CH
3)
2Cl] carry out dehydration reaction, the purity and the yield of the F 81097 that obtains all are significantly improved, simultaneously because the raising of F 81097 purity also has tangible influence to the post component efficiency of back, thereby the total recovery of vinorelbine is improved, and total recovery can be original 20% brings up to more than 30%.
The synthetic F 81097 of the present invention and prepare vinorelbine and the method for pharmacologically acceptable salt comprises the steps:
(1). vinealeucoblastine(VLB) (I) carries out dehydration reaction and obtains F 81097 (II) under the effect of Weir David Smail reagent:
Wherein
Be reflected in the polar solvent and carry out, described polar solvent can be lower alcohol, dimethyl formamide, and acetonitrile or their mixture etc., preferred acetonitrile, reaction conditions are comparatively gentle, do not need deep cooling, can carry out at normal temperatures;
(2). F 81097 (II) is carried out halogenation such as bromination reaction obtains compound (III):
Wherein
Bromide reagent can use phthalic imidine bromide (NBS), and its usage quantity can be reduced to theoretical amount reduces impurity relatively;
(3). contract ring reaction of compound (III) is obtained vinorelbine, if desired, the vinorelbine development of evil in febrile disease can be become its pharmacologically acceptable salt such as tartrate:
Wherein
Another characteristics of the present invention are dewatering agent Weir David Smail reagent ([ClCH=N (CH
3)
2Cl]) join in the vinealeucoblastine(VLB) dehydration reaction after being produced, handle like this, not only improve the productive rate of dehydration reaction, and reduced side reaction and product thereof, simplify the treatment step of subsequent reactions thus, improved the overall yield of vinorelbine and pharmacologically acceptable salt thereof.
The dewatering agent chloromethane fork alkyl dimethyl ammonium chloride ([ClCH=N (CH that the present invention uses
3)
2Cl]) can obtain by using dimethyl formamide (DMF) and chlorination reagent prepared in reaction in organic solvent such as chlorination sulfoxide or oxalyl chloride:
Reaction requires anhydrous condition, and organic solvent can be ether, tetrahydrofuran (THF), acetonitrile or their mixture etc., preferred ether.
Great advantage of the present invention is the change of the first step dehydration reaction reagent, has improved the productive rate of reaction widely, thereby the productive rate of synthetic vinorelbine is provided widely, because vinorelbine complex structure, synthetic difficulty is big, and therefore, method of the present invention has good economic worth.
The invention will be further described below by embodiment.It should be understood that the described preparation method of the embodiment of the invention is only used for illustrating the present invention, rather than limitation of the present invention, the simple modifications to preparation method of the present invention under design prerequisite of the present invention all belongs to the scope of protection of present invention.Except as otherwise noted, the percentage ratio among the present invention is molecular fraction.
Embodiment 1: by vinealeucoblastine(VLB) (I) preparation F 81097 (II)
(1). the inventive method:
A. prepare Weir David Smail reagent (Vilsmeier Reagent) chloromethane fork alkyl dimethyl ammonium chloride
In the 5000ml reaction flask, add 3.3 liters of anhydrous diethyl ethers and 112 gram dimethyl formamides (DMF is in advance through dehydration), stir and be added dropwise to 195 gram oxalyl chlorides down, react and be evaporated to dried 140 after one hour and restrain the reagent products;
B. with Weir David Smail reagent the Vinblastine sulphate dehydration is prepared F 81097
Wherein
Under nitrogen protection; the Vilsmeier Reagent reagent and the 60ml DMF that prepare among the 48 gram step a are added in the reaction flask; stir down in 0 ℃ of acetonitrile (460ml) solution that adds sulfur acid vinealeucoblastine(VLB) (I) 22 grams (24.2mmol); reaction solution was in 10 ℃ of reactions 2 hours; rose to room temperature reaction again 6 hours; reaction is cooled to 0 ℃ after finishing; add the 800ml frozen water; and regulate pH to 9 with ammoniacal liquor; ether extraction, washing, organic phase concentrates to such an extent that (II) 20 restrains; HPLC purity is 80%, and yield is 83%.
(2). the comparative example
Under nitrogen protection; raw material sulphuric acid vinealeucoblastine(VLB) (I) 18 grams (19.8mmol) are dissolved among the 240ml DMF; be chilled to-40 ℃ of DMF (60ml) solution that are added dropwise to 36ml (0.497mol) SOCL2, be warming up to 0 to 5 ℃ of stirring reaction after dripping off 12 hours, be chilled to again below 5 ℃; stir and add the 720ml frozen water down; transfer pH to 9 with strong aqua, ether extraction, washing; water concentrates to such an extent that solid product (II) 13 restrains, and HPLC purity is 67%.Yield 55%.
The impurity of relative retention time (with respect to vinorelbine alkali) 0.86 is reduced to below 3% of method (1) (this impurity post branch is difficult to remove) by 10% of method (2), has improved the yield that post divides widely.
Embodiment 2: prepare compound (III) by F 81097 (II) bromination
Wherein
Under nitrogen protection; 20 gram F 81097s (II) (HPLC purity is 80%) are joined in the reaction flask; add the stirring of 400ml methylene dichloride and make its dissolving; after reducing to 0 ℃; methylene dichloride (100ml) solution that adds trifluoroacetic acid (13ml); be cooled to-55 ℃; (NBS, methylene dichloride 3.6g) (250ml) solution drip off back stirring reaction 10 minutes under this temperature slowly to be added dropwise to the phthalic imidine bromide; after TLC shows that raw material disappears; add saturated sodium bicarbonate aqueous solution 1200ml, layering, organic phase washes with water to neutrality; concentrate to do to such an extent that 18 digest compound (III), directly drop into next step reaction.
Embodiment 3: by compound (III) preparation vinorelbine alkali (VI) compound
Wherein
Under nitrogen protection; above-mentioned bromide 18g (III) is joined in the reaction flask, add the dissolving of 1000ml tetrahydrofuran (THF), add the aqueous solution (150ml) of 5 gram tetrafluoro boron silver again; be warming up to 50 ℃ of reactions 40-60 minute; TLC reduces to room temperature after showing that raw material disappears, and filters; filtrate is transferred pH to 8.5-9 with saturated sodium bicarbonate; chloroform extraction is concentrated into dried vinorelbine alkali (IV) 16.8 grams, and HPLC purity is more than 76%.
To go up vinorelbine alkali (IV) 16.8 gram upper props, 80 gram alkali alumina posts are used the eluent wash-out then, collect product purity 90% (HPLC) above (can only obtain 80-85% originally), concentrate do 14 grams.
Divide on the product 400 grams thin silicagel column the 14 gram alumina columns that obtain, the eluent wash-out is collected purity and is being concentrated after doing to such an extent that 8.5 restrain 97% or more.(this step post branch purity of former technology is having only 6.5 grams more than 97%, and post divides cycle and the more former technology of raw material consumption all to shorten dramatically and reduces)
With the 80 gram alkali alumina posts on the 8.5 gram products more than 97% that obtain, eluent wash-out is then collected purity and is component 99.5% or more and concentrates and do to such an extent that 6.6 restrain.Embodiment 2 embodiment 3 merging total recoverys are 42% after above processing.
Embodiment 4: the crystallization of preparation preparing vinorelbine tartrate (V)
Wherein
The purity that embodiment 3 is obtained is added dropwise to the tartaric acetone soln 120ml of 2.41 grams after 99.5% above product 6.6 gram IV are with the 33ml acetone solutions, filter, filtrate decompression is concentrated into crystallization and separates out, and refrigerator is freezing to make crystallization complete, filters, dry to such an extent that 7.92 digest compound (V), yield 87%.
The synthetic total recovery 30.4% of embodiment 1-4.
Claims (8)
1. method for preparing F 81097 or its pharmacologically acceptable salt comprises:
Vinealeucoblastine(VLB) (I) is carried out dehydration reaction obtain F 81097 (II) under the effect of Weir David Smail reagent:
Wherein
2. according to weighing and requiring 1 method, its feature joins in the reaction system at the Weir David Smail reagent that will prepare.
3. according to the method for claim 2, it is characterized in that Weir David Smail reagent is the chloromethane fork alkyl dimethyl ammonium chloride for preparing.
4. according to the method for one of claim 1-3, it is characterized in that being reflected in the polar solvent and carry out.
5. according to the method for claim 4, wherein polar solvent is selected from lower alcohol, dimethyl formamide, acetonitrile or their mixture.
6. according to the method for claim 5, it is characterized in that described polar solvent is an acetonitrile.
7. Weir David Smail reagent is used for being synthesized by vinealeucoblastine(VLB) the purposes of F 81097 as dewatering agent.
8. according to the purposes of claim 7, its feature is the chloromethane fork alkyl dimethyl ammonium chloride for preparing in becoming your David Smail reagent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03136439 CN1245409C (en) | 2003-06-03 | 2003-06-03 | Preparation of dehydrate catharahhine from intermediate of vinorelbine synthesis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03136439 CN1245409C (en) | 2003-06-03 | 2003-06-03 | Preparation of dehydrate catharahhine from intermediate of vinorelbine synthesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1552715A true CN1552715A (en) | 2004-12-08 |
| CN1245409C CN1245409C (en) | 2006-03-15 |
Family
ID=34323337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03136439 Expired - Lifetime CN1245409C (en) | 2003-06-03 | 2003-06-03 | Preparation of dehydrate catharahhine from intermediate of vinorelbine synthesis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1245409C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2730521C2 (en) * | 2016-03-09 | 2020-08-24 | Синбиас Фарма АГ | Vinorelbine monotartrate and its pharmaceutical application |
| CN112552319A (en) * | 2020-12-22 | 2021-03-26 | 海南长春花药业有限公司 | Preparation method of vinorelbine tartrate |
-
2003
- 2003-06-03 CN CN 03136439 patent/CN1245409C/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2730521C2 (en) * | 2016-03-09 | 2020-08-24 | Синбиас Фарма АГ | Vinorelbine monotartrate and its pharmaceutical application |
| CN112552319A (en) * | 2020-12-22 | 2021-03-26 | 海南长春花药业有限公司 | Preparation method of vinorelbine tartrate |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1245409C (en) | 2006-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1724511A (en) | Method of extracting capsaicin and capsaithin from red pepper | |
| CN1990461A (en) | Industrial preparation method for 3-amino-2, 2-dimethyl propionamide | |
| CN1245409C (en) | Preparation of dehydrate catharahhine from intermediate of vinorelbine synthesis | |
| CN1552716A (en) | Synthesis of vinorelbine | |
| CN110423257B (en) | Sofosbuvir synthesis process | |
| CN1679586A (en) | Novel synthesis and crystallization of piperazine ring-containing compounds | |
| CN110551144B (en) | Preparation method of amoxicillin | |
| CN110078728B (en) | Abamebactam intermediate, preparation method and application thereof | |
| CN113135876A (en) | Preparation method of eribulin and intermediate thereof | |
| CN116283513A (en) | Preparation method of dapagliflozin intermediate ortho-isomer impurity | |
| CN110229111B (en) | Ambroxol impurity and preparation method and application thereof | |
| CN100364997C (en) | Vinorelbine preparation method | |
| CN104557965B (en) | Preparation technology for beta-artemether | |
| CN111116503A (en) | Preparation method of high-purity micafungin intermediate | |
| CN106045995A (en) | Synthesizing method of 5-bromine-1H-pyrrolo[2,3-b]pyridine | |
| CN113214267B (en) | Refining method for preparing pure and optically enriched eszopiclone | |
| CN1376159A (en) | Method for the preparation of anti-tumor Etoposide | |
| CN100364965C (en) | Process for preparing phenol addition compound cyanate of dicyclopentadiene | |
| CN1228340C (en) | Method for purifying 20(S)-camptothecin | |
| CN111675641B (en) | Monocyclic beta-lactam compound, monocyclic lactam compound salt and preparation method thereof | |
| CN111039959B (en) | Method for purifying BCN (BCN-cefcapene pivoxil precursor | |
| CN116284190A (en) | Pseudo-uridine intermediate, and preparation method and application thereof | |
| CN1284959A (en) | Process for purifying solution of ampicillin pro-drug ester | |
| CN1164557C (en) | Prepn of dibromochrysanthemic acid | |
| CN114213261A (en) | Preparation method of 4-methoxy-2-nitroaniline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060315 |
|
| CX01 | Expiry of patent term |